DNA acquires ZY for $2.94/sh* in stock—a 47% premium to Friday’s close: https://www.prnewswire.com/news-releases/ginkgo-to-acquire-zymergen-301592281.html The nominal deal value is $300M. ZY is a basket case (#msg-165257288), so this is a good deal for shareholder, IMO. *Based on 7/22/25 closing price.